Moneycontrol PRO
UPCOMING EVENT:Are you 45+? Planning for retirement? We have just the right webinar for you - Planning for Retirement with Life Insurance on 27-Jan, 3pm. Register now!
you are here: HomeNewsWorld

COVID-19 vaccine | Britain nears 500 million pound deal with GSK, Sanofi: Report

Britain is considering an option to buy the vaccine if human trials, which are due to begin in September, are successful.

July 05, 2020 / 02:02 PM IST
2 | Next crop of COVID-19 vaccine developers take more traditional route: The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs. The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop. Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.

2 | Next crop of COVID-19 vaccine developers take more traditional route: The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs. The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop. Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.

Britain is in talks with pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi to supply 60 million doses of coronavirus vaccine, The Economic Times reported.

The deal is valued around 500 million pounds or $624 million.

According to the daily, Britain is considering an option to buy the vaccine if human trials, which are due to begin in September, are successful.

Also Read: COVID-19 vaccine launch by Aug 15 unfeasible, ICMR slammed for raising ‘unrealistic hope and expectations’

The money would be paid in tranches as the development of the vaccine progresses with the final payment to be made on delivery.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The deal is expected to be announced in the coming days, the report added.

Moneycontrol could not independently verify the report.

Also Read: COVID-19 vaccine: ICMR confirms Covaxin launch likely by August 15, clinical trials fast-tracked

GSK and Sanofi are among more than 100 global players working on vaccines against COVID-19, which has killed more than half a million people worldwide.
Moneycontrol News
first published: Jul 5, 2020 02:02 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark